Saturday, November 26, 2022

Ought to You Put money into Novo Nordisk A/S (NVO) Inventory?

Must read

ClearBridge Investments, an funding administration firm, revealed its “ClearBridge Worldwide Development ADR Technique” third quarter 2022 investor letter. A duplicate of the identical may be downloaded right here. The technique outperformed its benchmark within the third quarter, the MSCI EAFE Index. General inventory choice and sector allocation attributed to the technique’s efficiency within the quarter. As well as, please test the fund’s high 5 holdings to know its greatest picks in 2022.

ClearBridge Investments highlighted shares like Novo Nordisk A/S (NYSE:NVO) in its Q3 2022 investor letter. Headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a pharmaceutical firm that operates in Diabetes and Weight problems care, and Biopharma segments. On November 22, 2022, Novo Nordisk A/S (NYSE:NVO) inventory closed at $115.38 per share. One-month return of Novo Nordisk A/S (NYSE:NVO) was 6.67% and its shares gained 5.45% of their worth during the last 52 weeks. Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $259.853 billion.

ClearBridge Investments made the next remark about Novo Nordisk A/S (NYSE:NVO) in its Q3 2022 investor letter:

“The proceeds from our repositioning gross sales proceed to be put to work throughout the Technique’s secular and structural development buckets. Particularly, we’ve been including extra to secular, high quality compounders corresponding to Danish biotech firm Novo Nordisk A/S (NYSE:NVO) and Japanese medical tools provider Olympus (OTCPK:OCPNF). These corporations have sturdy stability sheets, good money movement technology and important pricing energy, traits that ought to allow them to get stronger via the storm impacting worldwide equities.”

Novo Nordisk A/S (NYSE:NVO) will not be on our checklist of 30 Most Common Shares Amongst Hedge Funds. As per our database, 40 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) on the finish of the third quarter, which was 32 within the earlier quarter.

We mentioned Novo Nordisk A/S (NYSE:NVO) in one other article and shared the very best European dividend shares to spend money on. As well as, please take a look at our hedge fund investor letters Q3 2022 web page for extra investor letters from hedge funds and different main traders.


Recommended Articles:

Disclosure: None. This text is initially revealed at Insider Monkey.

Supply hyperlink

More articles


Please enter your comment!
Please enter your name here

Latest article